weSure Global Tech 2025: Ayalon Already Generates The Profit, The US And Credit Still Need Proof

Getting To Know The Company

weSure Global Tech can no longer be read correctly as a single digital insurer. In 2025 it is first and foremost a financial holding platform centered on Ayalon, with three surrounding growth options that still have not passed a full economic proof test: the US activity after the Hourly deal, the new non-bank credit arm, and the move into provident-fund management. What works today is Ayalon. What excites the market is everything around Ayalon. What still blocks a cleaner thesis is the gap between those two layers.

The first read looks strong: gross written premiums of NIS 5.049 billion, insurance service revenue of NIS 4.889 billion, total comprehensive income of NIS 393.9 million, and comprehensive income attributable to shareholders of NIS 265.3 million. Attributable equity rose to NIS 1.247 billion and ROE reached 25.7%. On top of that, Ayalon entered this stage with a 136% solvency ratio as of June 2025, a capital surplus of NIS 675 million, and a dividend policy that targets at least 40% of annual comprehensive profit as long as its capital target is maintained.

But that surface-level read misses the core issue. The listed company still has not proved that its newer growth layers can generate real economics. Almost all shareholder-attributable profit still comes from the Ayalon holding, while the US activity is still not material in sales, the credit arm only received its license after the balance-sheet date, and Ayalon Gemel received its management-company license only at the end of March 2026. In other words, weSure in 2025 is less “a digital insurance breakout” and more “a profitable Israeli insurer with a package of options built around it.”

That is exactly what makes 2025 such an important year. Anyone drawn to this story sees three things that already work: Ayalon is improving underwriting in general insurance, maintaining capital headroom that allows distributions, and generating a capital base that gives the group room to launch new businesses. Anyone staying cautious sees three open frictions: a meaningful part of the profit improvement came through the capital markets and financial margin, weSure Insurance itself weakened, and the newer businesses still need operating proof. Over the next 2 to 4 quarters the market will have to answer one simple question: can weSure turn Ayalon from a single earnings engine into a broader financial platform, or is it still mainly Ayalon wrapped in a growth narrative.

The Group's Economic Map

Five non-obvious findings define 2025:

1. Almost the entire profit of the listed company came from Ayalon. At the parent-only level, profit from investees reached NIS 280.3 million, while profit attributable to the company’s shareholders was NIS 265.6 million. That means the activities outside Ayalon are still not carrying the case.
2. The earnings improvement was not only underwriting. Investment and financing profit rose to NIS 397.3 million from NIS 194.6 million. That helped a lot in 2025, but it also makes normalization more relevant.
3. weSure Insurance itself weakened. Its core profit fell to NIS 21.7 million from NIS 30.4 million, and in the fourth quarter it already moved to a core loss of NIS 1.16 million.
4. The US platform expanded, but still has not become an earnings base. Hourly and MDS added real infrastructure, but the company itself says cumulative US sales are still not material.
5. The group cleaned up the old bank-loan story, but did not become simpler. Instead of an acquisition bank loan with covenants, the structure now includes public bonds, equity raises, dividends from Ayalon, and fresh commitments around the US and credit.

Events And Triggers

Hourly Expanded The Structure, Not Yet The Proof

The standout move of 2025 was the completion of the Hourly deal in September. Through WUS, the group brought in Hourly, the MDS payroll company, and the remaining AmTrust stake in WUD. After completion, WUS holds two payroll companies and two insurance underwriting agencies, and the company remained the controlling shareholder in WUS with 39.5% on a fully diluted basis and the right to appoint most directors. AmTrust holds 22.5%, and the previous Hourly investors hold the remaining 38%.

There is clear strategic logic here. The company is trying to connect payroll with workers’ compensation, meaning the employer’s wage base with an insurance product that is priced off that same base. If that model works, it can create stronger underwriting, better data, and a more powerful embedded product. The company also states that total equity increased by about NIS 41 million following the first-time consolidation of Hourly and MDS in the fourth quarter.

But the gap between structure and results is still wide. The company explicitly states that cumulative sales of the US subsidiaries are still not material as of the reporting date. That means Hourly should still be read as infrastructure creation, not as economic proof. That is not a side comment. It is the core of the US question.

The US Also Got A Carrier Option, But Still Not A Deal

In August 2025 the company signed a non-binding memorandum of understanding to acquire USICOA, a group that holds a US insurer active in property and casualty coverage for small and medium-sized businesses. The acquisition price was estimated at around $7 million based on equity, with $2 million to be held in escrow for two years to handle claim-related adjustments. As of the report date, due diligence had not yet been completed and no binding agreement had been signed.

The implication is two-sided. On the one hand, this expands the option from MGA to carrier, meaning from underwriting and distribution without meaningful capital lockup to a model that could provide more direct control over the product. On the other hand, this is exactly the kind of move that can sound bigger before it becomes real. For now it is still an option, not a foundation stone of the thesis.

Credit And Provident Funds Moved From Idea To License

The second development that materially changes the reading is what happened around the newer Israeli businesses. Glovaltak Finance was set up in August 2025 to target financing and guarantees for small and medium-sized businesses. The company invested NIS 5 million through a subordinated capital note, advanced a business-separation arrangement with Ayalon, and in February 2026 signed an intercompany credit line of up to NIS 50 million to support the launch. On March 26, 2026 it received an expanded credit license as well as a license to issue guarantees, and the controlling shareholders received the relevant control permit.

At the same time, on March 31, 2026 Ayalon Provident Funds received a provident-fund management-company license, and the controlling shareholders received an updated control and holding permit that also covers Ayalon Gemel. That is a material shift. By the end of 2025 the group was still talking about expanding into new verticals. By the end of March 2026 it had already received two new licenses in practice.

The trigger is positive, but not one-directional. A license is a condition of entry, not a proof of return. Non-bank credit can open a new engine, but it can also demand capital, risk governance, and discipline. Provident-fund management can broaden Ayalon’s distribution platform, but it also requires operating setup and real customer acquisition. So the immediate meaning of 2026 is not “more earnings engines.” It is “more execution tests.”

Dividends And Capital Raises Changed The Allocation Layer

2025 was also an aggressive capital-allocation year. Ayalon distributed NIS 155 million of dividends during 2025, of which the company’s share amounted to about NIS 105 million. At the same time, the company itself distributed NIS 65 million to its own shareholders. In addition, it issued Series A bonds and warrants to the public for gross proceeds of NIS 166.2 million, later expanded the bond series so that NIS 199.6 million par value was outstanding by year-end, and in December 2025 completed a private placement of shares for gross consideration of about NIS 150 million. Ayalon itself also completed a separate private placement of shares and warrants in August 2025 for about NIS 150 million.

The right way to read all of this is not “the company raised money because it is weak.” The right reading is different: the group chose in 2025 to accelerate expansion. But when expansion is funded through upstream dividends, public bonds, and fresh equity, the thesis shifts from pure growth to the quality of capital allocation.

Efficiency, Profitability And Competition

The central story of 2025 is not just that profit rose. The central story is where it rose from. At the group level, insurance service result increased to NIS 363.5 million from NIS 289.6 million, and that is a real operating improvement. But in the same year, investment and financing profit jumped to NIS 397.3 million from NIS 194.6 million. That means 2025 was a good underwriting year, but also a year that received meaningful support from the capital markets and financial margin.

Ayalon Is Carrying 2025

In Ayalon’s general insurance business, core profit rose to NIS 340.4 million from NIS 273.2 million. In the fourth quarter, it rose to NIS 77.8 million from NIS 46.7 million. The improvement came mainly from motor liability, motor property, and the rest of the book, with better prior-year claims development and stronger mix in professional liability, contractors, and guarantees.

Life and health also improved, but the quality is more mixed there. In life insurance and long-term savings, pre-tax comprehensive profit rose to NIS 109.7 million from NIS 96.4 million, while core profit actually slipped slightly to NIS 100.3 million from NIS 102.1 million. The gap was closed by the excess financial margin, which moved from negative NIS 6.4 million to positive NIS 8.8 million. In health, the jump was much sharper: pre-tax comprehensive profit of NIS 98.2 million versus NIS 18.0 million in 2024, with strong improvement in both core profit and financial margin.

That matters because it is not the same earnings quality across the segments. In general insurance, Ayalon looks like a stronger underwriting engine. In life and health, the improvement also leans on CSM and on the capital markets. Life and health CSM rose to NIS 1.059 billion at the end of 2025 from NIS 1.014 billion at the end of 2024, which clearly supports future earnings potential. But it is still not the same quality as hard underwriting profit in general insurance.

weSure Insurance No Longer Looks Like The Clean Growth Engine

One of the most important numbers in the filing sits not in Ayalon, but in weSure Insurance itself. Core profit fell to NIS 21.7 million from NIS 30.4 million, and in the fourth quarter the company already moved to a core loss of NIS 1.16 million versus a profit of NIS 2.95 million in the comparable quarter. The explanation is straightforward: worse reinsurance terms damaged profitability in both motor liability and motor property, even though there was some improvement in gross underwriting.

That stands out particularly in motor property. weSure Insurance’s combined ratio moved to 95% gross and 99% retained, versus 94% and 96% in 2024. In the fourth quarter the picture was already weaker at 101% gross and 103% retained. That is an important reminder: the original digital insurance brand still exists, but it no longer explains the economics of 2025.

The Real Competition Is Not Only Between Insurers, But Between Uses Of Capital

This is the less visible point. weSure in 2025 is not only competing against other insurers. It is also competing with itself over how to allocate capital. Ayalon already knows how to show profit, capital surplus, and dividends. The US operation, Glovaltak Finance, and Ayalon Gemel still require capital, management attention, and time. So every major strategic decision has a two-sided effect: every shekel that funds a new option is also a shekel that is not left available for dividends, de-leveraging, or reinforcing an existing engine.

Cash Flow, Debt And Capital Structure

In weSure’s case the more relevant framework is all-in cash flexibility, meaning how much room is actually left after all real cash uses and obligations. The reason is simple: the heart of the thesis is not “how much cash the existing business can theoretically generate before management decisions,” but how much freedom the parent still has after dividends, capital raises, repayments, acquisitions, and investment in the new platforms.

At The Group Level, Cash Rose, But Not Only Through Operations

On a consolidated basis, cash and cash equivalents rose to NIS 1.252 billion from NIS 790.5 million. Cash flow from operations rose to NIS 278.3 million from NIS 176.5 million, investing cash flow was negative NIS 118.3 million, and financing cash flow was positive NIS 301.6 million versus just NIS 11.3 million in 2024.

That means the cash build should not be read in isolation. The company itself explicitly says financing cash flow was affected by share issuance, share allocation in consolidated entities, receipts on account of shares, proceeds from bonds and subordinated notes, alongside dividends paid and the repayment of bonds and other loans. So 2025 is a year in which cash increased, but a meaningful part of the flexibility was built through the capital structure rather than purely through operating cash generation.

The Parent-Level Picture Is Cleaner And More Revealing

At the solo level, where the real capital-allocation question sits, the company ended 2025 with current assets of about NIS 371 million, of which about NIS 369 million were cash and cash equivalents. Against that, total solo financial liabilities to non-bank entities and the public stood at about NIS 251 million, with only NIS 32 million of current liabilities.

The interesting part is the shape of the debt. During 2025 the company repaid in full the NIS 90 million bank loan that had originally been used to acquire control of Ayalon, and with it the old covenants and collateral were released. That is a real improvement. But at the same time there remained a seller loan with NIS 25 million of principal outstanding, an assigned-rights-and-loan arrangement with Rahmani Investments with NIS 39.3 million outstanding, and Series A bonds amounting to NIS 199.6 million.

In other words, weSure ended 2025 without the old bank-loan overhang, but not without leverage. The debt simply changed shape.

Ayalon Generates The Value That Can Actually Be Moved Upstream

This is the important positive point in the case. This is not a classic holding company with trapped value and no upstream access. Ayalon already showed in 2025 that it can send cash upward: NIS 30 million relating to 2024, plus NIS 75 million and NIS 50 million relating to 2025. weSure’s share of those three distributions was about NIS 105 million. On top of that, Ayalon’s dividend policy targets at least 40% of annual comprehensive profit as long as the capital target is maintained.

That matters because it reduces one of the classic holding-company problems. At the same time, it sharpens the question of where that upstream cash goes. In 2025 part of the answer was NIS 65 million distributed to weSure’s shareholders, and another part was used to finance growth, public bonds, the US expansion, and the new credit platform.

This Is Not Pure Balance-Sheet Strength, It Is Balance-Sheet Strength That Requires Discipline

The cleanest way to frame it is this: the end-2025 structure is less pressured than the old version, but more complex. On one side, the company has solo cash, no longer has the old bank loan, and Ayalon itself comes with capital surplus and dividends. On the other side, that same flexibility is already partly spoken for by more projects, more operating arms, and more capital decisions.

That is why the 2026 test is not whether the company has cash. It does. The real test is whether it knows how to allocate that cash so that the value created inside Ayalon does not get scattered too quickly across options that still have not proved their return profile.

Outlook

Before moving into 2026, four points need to be fixed in place:

1. Ayalon is already at the profit stage, not the promise stage.
2. The US business, credit, and provident-fund activity are still at the promise stage, not the profit stage.
3. 2025 also benefited from a supportive financial backdrop, so 2026 will be judged on normalization rather than simple continuation.
4. The main question is not whether the company can add more engines, but whether it can add them without damaging capital quality.

For that reason, 2026 looks like a proof year for capital allocation. Not a proof year for Ayalon. Ayalon already proved in 2025 that it can generate profit, keep surplus capital, and distribute dividends. The proof year is for the layers above and around it.

What Needs To Happen At Ayalon For The Base To Stay Strong

The whole thesis rests on Ayalon continuing to produce enough underwriting profit even if the financial tailwind becomes more moderate. That requires two things: continued execution in general insurance, especially in the lines that improved on a core basis, and a capital-management path that still allows distributions. The student accident tender, with estimated annual premium of about NIS 186 million, weSure Insurance’s continued win in the state-employee motor tender for 2026, and the updated license allowing weSure Insurance to enter travel insurance all add room for expansion. But the market will not be satisfied with headlines alone. It will want to see that those moves translate into sensible earnings after pricing and risk.

What Needs To Happen In The US For The Option To Become An Asset

The US platform needs to move from “we have built the structure” to “we have built the economics.” That can happen in one of two ways, or through some combination of both. The first is organic proof: Hourly, MDS, and WUD need to start showing material sales and clearer commercial traction, and the payroll plus workers’ compensation model needs to prove that it really creates an advantage. The second is structural: the carrier route needs to become more concrete through USICOA or some other transaction. Until one of those paths becomes real, the US will remain a story with upside, not an engine that meaningfully moves earnings.

What Needs To Happen In The New Israeli Vertical Arms

Glovaltak Finance and Ayalon Gemel have already crossed the licensing stage. Now comes the execution stage. For Glovaltak Finance, the first question is quality of growth: will the intercompany line of up to NIS 50 million allow for a controlled and disciplined launch, or will it quickly become an open-ended capital need. For Ayalon Gemel, the first question is commercial: does the license turn into real distribution and assets under management, or does it remain strategically sensible on paper but too slow economically.

What The Market May Start Pricing In The Near Term

In the coming days, weeks, and quarters the market will focus on four things:

1. whether 2025 profit can be trusted without a similarly strong financial tailwind,
2. whether Ayalon can keep distributing cash without weakening its solvency cushion,
3. whether the US starts showing a first material business datapoint rather than just more structure,
4. whether credit and provident funds become operating businesses rather than just licensed concepts.

That is exactly why 2026 matters more than the attractive headline numbers of 2025. The coming year will test whether weSure knows how to build a platform, or only how to add platforms.

Risks

Economic Concentration In Ayalon

The first and clearest risk is concentration. At the parent-only level, almost the entire profit came from investees, meaning from Ayalon. That is positive as long as Ayalon continues to work, but it also means weakness elsewhere in the structure is still not being offset by meaningful independent profit.

Normalization Risk In The Capital Markets And Financial Margin

In 2025 the financial margin and investment line contributed much more than in 2024. That is legitimate, but it also means 2025 should not be read as if it were all underwriting. If 2026 arrives with more moderate market returns or a less supportive yield-curve backdrop, the bottom line can look materially less generous even without any underwriting deterioration.

US Execution Risk

The company has expanded the US structure, but still without a material sales base. That is exactly the stage where execution risk is highest: more management layers, more integration, more strategic directions, and still limited proof of earnings. USICOA, if it progresses, would add underwriting and regulatory risk alongside the upside.

Capital Allocation And Dilution Risk

2025 showed that the company knows how to raise both debt and equity. That is an advantage. But it is also a reminder that the growth layers around Ayalon still do not fund themselves. Public bonds, warrants, private placements, and upstream dividends are useful tools, but repeated use of them can turn platform growth into recurring capital appetite.

Competition And Reinsurance Terms At weSure Insurance

weSure Insurance showed in 2025 that even when there is some underwriting improvement, weaker reinsurance terms can absorb a large part of the benefit. If those terms remain difficult in 2026 as well, it will be hard to restore this activity to the status of a meaningful earnings engine.

Regulatory And Operating Risk In The New Vertical Arms

Receiving a license is a beginning, not an endpoint. Non-bank credit and provident funds are both businesses that punish operating mistakes, weak risk governance, and poor capital discipline quickly. The group is broadening its strategic footprint, but also its execution load.

Short Sellers' View

At the market level, short interest does not signal acute stress. As of March 27, 2026, short interest stood at 0.62% of float with SIR of 2.05. That is below the sector average short float of 0.86% and close to the sector-average SIR of 1.952. Even after a relatively quick rise from late 2025, the position has returned to moderate levels. This is not the profile of a stock the market is aggressively leaning against. It is more a picture of ordinary skepticism toward a complex story.

The implication is that the market is not reading this as a near-term blow-up. It is simply not giving full credit yet to every growth layer. That actually fits the thesis well: Ayalon has already earned a certain level of trust, but the newer layers still have not.

---

Conclusions

weSure in 2025 looks meaningfully better than weSure in 2024, but for a less romantic reason than the brand name might suggest. What supports the thesis today is Ayalon: better underwriting in general insurance, capital surplus, dividends, and a profit base that can carry the listed company. What still blocks a stronger thesis is that the US activity, credit, and provident funds have not yet proved their economics, while 2025 also benefited from a supportive financial backdrop.

Current thesis: weSure is currently mainly a profitable Ayalon holding with an outer layer of growth options. For that outer layer to justify additional value, it has to start generating returns rather than just structure.

What changed: in 2024 weSure still looked like a group trying to rebuild its capital base after the Ayalon transformation. In 2025 Ayalon already generated profit, dividends, and capital surplus, and the group used that position to expand into the US, non-bank credit, and provident funds. The question is no longer whether there is a base. The question is whether the expansion of that base will be disciplined.

The counter-thesis: one can argue that Ayalon alone already generates enough profit, capital, and dividends to justify a large part of the story, making everything around it nearly free upside. That is a serious argument. But it assumes that the 2025 earnings level is sustainable even without a similar financial tailwind, and that the capital directed outward will remain disciplined.

What could change the market reading: the first sign of material US sales or a real carrier step, an orderly operating start at Glovaltak Finance and Ayalon Gemel, and continued upstream distributions from Ayalon without pressure on solvency.

Why this matters: the question in weSure is no longer whether a broad insurance and finance group can be built. The question is whether it can be built without damaging earnings quality, capital quality, and the accessibility of value to shareholders.

Over the next 2 to 4 quarters, three things need to happen together: Ayalon needs to preserve earnings quality and distributable capacity after 2025, the US activity needs to move from structure to result, and credit plus provident funds need to start operating without becoming capital sinks. If those three points come together, weSure can start being read as a broader financial platform. If not, 2025 will be remembered as the year in which Ayalon funded a wider story, but still did not prove it.